Survival rate of cervical cancer in Asian countries: a systematic review and meta-analysis.
Asian countries
Cervical cancer
Meta analysis
Survival rate
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
14 Dec 2023
14 Dec 2023
Historique:
received:
26
07
2023
accepted:
04
12
2023
medline:
15
12
2023
pubmed:
15
12
2023
entrez:
15
12
2023
Statut:
epublish
Résumé
Cancer is one of the main causes of death, and cervical cancer is the fourth most common cancer and the fourth leading cause of death from malignancy among women. Knowing the survival rate is used to evaluate the success of current treatments and care. This study was conducted to assess the survival rate of cervical cancer in Asia. This systematic survey was conducted on four international databases, including Medline/PubMed, ProQuest, Scopus, and Web of Knowledge, and includes manuscripts that were published until the end of August 2021. Selected keywords were searched for international databases including cervical neoplasms [mesh], survival analysis or survival or survival rate, Asian countries (name of countries). The Newcastle-Ottawa Qualitative Evaluation Form was used for cohort studies to evaluate the quality of the articles. The analysis process was performed to evaluate the heterogeneity of the studies using the Cochran test and I A total of 1956 articles were selected and reviewed based on their title. The results showed that 110 articles met the inclusion criteria. According to the randomized model, the 1, 3, 5, and 10-year survival rates of cervical cancer were 76.62% (95% Confidence Interval (CI), 72.91_80.34), 68.77% (95% CI, 64.32_73.21), 62.34% (95% CI, 58.10_66.59), and 61.60% (95% CI, 52.31_70.89), respectively. Additionally, based on the results of meta-regression analysis, there was an association between the year of the study and the survival rate, elucidating that the survival rate of cervical cancer has increased over the years. Results can provide the basic information needed for effective policy making, and development of public health programs for prevention, diagnosis, and treatment of cervical cancer.
Identifiants
pubmed: 38098009
doi: 10.1186/s12905-023-02829-8
pii: 10.1186/s12905-023-02829-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
671Subventions
Organisme : Shiraz University of Medical Sciences
ID : grant No. 1399-12-5-22520
Informations de copyright
© 2023. The Author(s).
Références
Zhang X, Zeng Q, Cai W, Ruan W. Trends of Cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019. BMC Public Health. 2021;21(1):894.
doi: 10.1186/s12889-021-10907-5
pubmed: 33975583
pmcid: 8114503
Song M, Hu FB, Spiegelman D, Chan AT, Wu K, Ogino S, Fuchs CS, Willett WC, Giovannucci EL. Long-term status and change of body fat distribution, and risk of Colorectal cancer: a prospective cohort study. Int J Epidemiol. 2016;45(3):871–83.
doi: 10.1093/ije/dyv177
pubmed: 26403814
Vafaeinezhad Z, Kazemi Z, Mirmoeini M, Piroti H, Sadeghian E, Mohammad Ali-Vajari M, Fattah N, Jafari M. Trends in Cervical cancer incidence in Iran according to national cancer registry. J Mazandaran Univ Med Sci. 2018;28(161):108–14.
Khorasanizadeh F, Hassanloo J, Khaksar N, Mohammad Taheri S, Marzaban M, Akbari Sari BHR, Zendehdel A. Epidemiology of Cervical cancer and human papilloma virus Infection among Iranian women - analyses of national data and systematic review of the literature. Gynecol Oncol. 2013;128(2):277–81.
doi: 10.1016/j.ygyno.2012.11.032
pubmed: 23200918
Tracy L, Gaff HD, Burgess C, Sow S, Gravitt PE, Tracy JK. Estimating the impact of human papillomavirus (HPV) vaccination on HPV prevalence and Cervical cancer incidence in Mali. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2011;52(5):641–5.
doi: 10.1093/cid/ciq190
Madeleine MM, Daling JR, Schwartz SM, Shera K, McKnight B, Carter JJ, Wipf GC, Critchlow CW, McDougall JK, Porter P, et al. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prevention: Publication Am Association Cancer Res Cosponsored Am Soc Prev Oncol. 2001;10(3):171–7.
Asthana S, Chauhan S, Labani S. Breast and Cervical cancer risk in India: an update. Indian J Public Health. 2014;58(1):5–10.
doi: 10.4103/0019-557X.128150
pubmed: 24748350
Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556–63.
doi: 10.1093/annonc/mdn642
pubmed: 19073863
Chen Z, Shi Y, Wang S, Lu Q. Meta-analysis showing that early response to neoadjuvant chemotherapy predicts better survival among Cervical cancer patients. Oncotarget. 2017;8(35):59609–17.
doi: 10.18632/oncotarget.19425
pubmed: 28938664
pmcid: 5601760
Nemati S, Saeedi E, Roshandel G, Nahvijou A, Badakhshan A, Akbari M, Sedaghat SM, Hasanpour-Heidari S, Hosseinpour R, Salamat F, et al. Population-based cancer survival in the Golestan province in the northeastern part of Iran 2007–2012. Cancer Epidemiol. 2022;77:102089.
doi: 10.1016/j.canep.2021.102089
pubmed: 35042146
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clinical Research ed). 2015;350:g7647.
pubmed: 25555855
Penson DF, Krishnaswami S, Jules A. Evaluation and Treatment of Cryptorchidism. Comparative Effectiveness Review No. 88. Prepared by the Vanderbilt Evidence-based Practice Center under Contract; 2012.
Bagos PG, Nikolopoulos GK. Mixed-effects Poisson regression models for meta-analysis of follow-up studies with constant or varying durations. Int J Biostatistics 2009, 5(1).
Harris RJ, Deeks JJ, Altman DG, Bradburn MJ, Harbord RM, Sterne JA. Metan: fixed-and random-effects meta-analysis. Stata J. 2008;8(1):3–28.
doi: 10.1177/1536867X0800800102
Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74(3):785–94.
doi: 10.1111/biom.12817
pubmed: 29141096
Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. The Lancet. 2019;393(10167):169–82.
doi: 10.1016/S0140-6736(18)32470-X
Balasubramaniam G, Gaidhani RH, Khan A, Saoba S, Mahantshetty U, Maheshwari A. Survival rate of Cervical cancer from a study conducted in India. Indian J Med Sci. 2020;73(2):203–11.
Aswathy S, Quereshi MA, Kurian B, Leelamoni K. Cervical cancer screening: current knowledge & practice among women in a rural population of Kerala, India. Indian J Med Res. 2012;136(2):205.
pubmed: 22960886
pmcid: 3461731
Wenzel L, DeAlba I, Habbal R, Kluhsman BC, Fairclough D, Krebs LU, Anton-Culver H, Berkowitz R, Aziz N. Quality of life in long-term Cervical cancer survivors. Gynecol Oncol. 2005;97(2):310–7.
doi: 10.1016/j.ygyno.2005.01.010
pubmed: 15863123
Selvaggi L, Loizzi V, Di Gilio A, Nardelli C, Cantatore C, Cormio G. Neoadjuvant chemotherapy in Cervical cancer: a 67 patients experience. Int J Gynecologic Cancer. 2006;16(2):631–7.
doi: 10.1111/j.1525-1438.2006.00396.x
Soetrisno S, Mulyani S, Nurinasari H, Budi E. The influence of psychocurative on Cortisol Level, anxiety, and Quality of Life in Advanced Stage Cervical Cancer patients. Folia Med Indonesiana. 2019;55(3):202–5.
doi: 10.20473/fmi.v55i3.15502
Wu X, Wu L, Han J, Wu Y, Cao T, Gao Y, Wang S, Wang S, Liu Q, Li H. Evaluation of the sexual quality of life and sexual function of Cervical cancer survivors after cancer treatment: a retrospective trial. Arch Gynecol Obstet. 2021;304(4):999–1006.
doi: 10.1007/s00404-021-06005-x
pubmed: 33616705
Chen C-P, Kung P-T, Wang Y-H, Tsai W-C. Effect of time interval from diagnosis to treatment for Cervical cancer on survival: a nationwide cohort study. PLoS ONE. 2019;14(9):e0221946.
doi: 10.1371/journal.pone.0221946
pubmed: 31483834
pmcid: 6726236
Behnamfar F, Azadehrah M. Factors associated with delayed diagnosis of Cervical cancer in iran-a survey in Isfahan city. Asian Pac J Cancer Prev. 2015;16(2):635–9.
doi: 10.7314/APJCP.2015.16.2.635
pubmed: 25684499
Mahantshetty U, Lavanya G, Grover S, Akinfenwa C, Carvalho H, Amornwichet N. Incidence, treatment and outcomes of Cervical cancer in low-and middle-income countries. Clin Oncol. 2021;33(9):e363–71.
doi: 10.1016/j.clon.2021.07.001
Garner EI. Cervical cancer: disparities in screening, treatment, and survival. Cancer Epidemiol Prev Biomarkers. 2003;12(3):242s–7.
Singh GK, Azuine RE, Siahpush M. Global inequalities in Cervical cancer incidence and mortality are linked to deprivation, low socioeconomic status, and human development. Int J MCH AIDS. 2012;1(1):17.
doi: 10.21106/ijma.12
pubmed: 27621956
pmcid: 4948158
Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination—review of current perspectives. Journal of oncology 2019, 2019:3257939. https://doi.org/10.1155/2019/3257939 . eCollection 2019.
Behtash N, Mehrdad N. Cervical cancer: screening and prevention. Asian Pac J Cancer Prev. 2006;7(4):683–6.
pubmed: 17250453
Kau Y-C, Liu F-C, Kuo C-F, Huang H-J, Li AH, Hsieh M-Y, Yu H-P. Trend and survival outcome in Taiwan cervical cancer patients: a population-based study. Medicine 2019, 98(11):e14848. https://doi.org/10.1097/MD.0000000000014848 .
Leath IIICA, Straughn JM Jr, Kirby TO, Huggins A, Partridge EE, Parham GP. Predictors of outcomes for women with cervical carcinoma. Gynecol Oncol. 2005;99(2):432–6.
doi: 10.1016/j.ygyno.2005.06.047
pubmed: 16137753
El-Hammasi K, Samir O, Kettaneh S, Al-Fadli A, Thalib L. Use of and attitudes and knowledge about pap smears among women in Kuwait. J Women’s Health. 2009;18(11):1825–32.
doi: 10.1089/jwh.2008.1227